Finger acupoint electrical stimulation for thinking and memory problems after stroke
Tests gentle electrical stimulation of finger acupoints in adults with cognitive impairment after stroke.
Plain-language title generated from the registry record
Registry title: Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
Key facts
- Where
- Tianjin, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 35 to 80 who had a stroke 2 weeks to 6 months ago and now have memory or thinking problems.
- Age
- 35 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Stroke 2 weeks to 6 months ago, with cognitive impairment shown by a Montreal Cognitive Assessment (MoCA) score below 26. No severe aphasia.
- Earlier treatment
- Cannot be taking other medicines that affect thinking and memory.
- Biomarker or test result
- MoCA score below 26.
Main reasons for not taking part
- Unstable vital signs or life-threatening illness
- Implanted device such as a pacemaker, defibrillator or deep brain stimulator
- History of epilepsy or seizures
- Pregnant or breastfeeding women
- Another brain or psychiatric disease as the main cause of the cognitive problems
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 80 years old?
Source: NCT07736885, who can take part
Where in China
- The First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Trial code
- NCT07736885
- Record updated
- 30 July 2026
- Original description
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.Read full original descriptionShow less
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.
Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.
Who can participate: Adults aged [35-80] who have had an ischemic stroke and now have mild to moderate cognitive impairment.
What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.
Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.
Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Inclusion: Aged 35-80 years; Stroke duration within 2 weeks to 6 months post-onset; Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26; Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.); No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study; Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.
Exclusion: Concurrent use of other medications affecting cognitive function; Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.); History of epilepsy or epileptic seizures; Allergy to the study intervention device or history of serious adverse reactions; Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.); Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis; Unstable vital signs or life-threatening comorbidities; Pregnant or lactating women.